Dr. Zamarin on the Future Treatment Landscape of Gynecologic Malignancies

Dmitriy Zamarin, MD, PhD
Published: Friday, Oct 13, 2017



Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future treatment landscape for patients with gynecologic malignancies.

According to Zamarin, the first drugs that will be approved will be more of the standard off-the-shelf treatments, such as immune checkpoint blockade or vaccines.

The adoptive T-cell therapies will be are more involved and more expensive, states Zamarin. The recent product that was approved from Novartis for the treatment of patients with leukemia is very expensive per treatment, which may become a limitation of choosing some of these therapies. If the therapies resolve in long-term disease stabilization or even cures of these patients, perhaps these types of treatments will justify the costs, explains Zamarin.
 


Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future treatment landscape for patients with gynecologic malignancies.

According to Zamarin, the first drugs that will be approved will be more of the standard off-the-shelf treatments, such as immune checkpoint blockade or vaccines.

The adoptive T-cell therapies will be are more involved and more expensive, states Zamarin. The recent product that was approved from Novartis for the treatment of patients with leukemia is very expensive per treatment, which may become a limitation of choosing some of these therapies. If the therapies resolve in long-term disease stabilization or even cures of these patients, perhaps these types of treatments will justify the costs, explains Zamarin.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x